Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis

• Published in: The Journal of clinical investigation Vol. 117; no. 10; pp. 3118 - 3127
• Main Authors: Choi, Jae Young, Joo, Nam Soo, Krouse, Mauri E., Wu, Jin V., Robbins, Robert C., Ianowski, Juan P., Hanrahan, John W., Wine, Jeffrey J.
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 01.10.2007
• Subjects: Acetylcholine - metabolism; Animals; Bacterial infections; Biomedical research; Carbachol; Carbachol - pharmacology; Cholinergic Agonists - pharmacology; Cyclic AMP - metabolism; Cystic fibrosis; Cystic Fibrosis - etiology; Cystic Fibrosis - metabolism; Cystic Fibrosis Transmembrane Conductance Regulator - metabolism; Dosage and administration; Drug Synergism; Exocrine Glands - drug effects; Exocrine Glands - secretion; Genetic aspects; Health aspects; Hogs; Humans; Infections; Mucus - secretion; Peptides; Physiology; Respiratory System - secretion; Risk factors; Swine; Vasoactive Intestinal Peptide - metabolism; Vasoactive Intestinal Peptide - pharmacology; Vasoactive intestinal peptides; United States

Cystic fibrosis (CF) is caused by dysfunction of the CF transmembrane conductance regulator (CFTR), an anion channel whose dysfunction leads to chronic bacterial and fungal airway infections via a pathophysiological cascade that is incompletely understood. Airway glands, which produce most airway mu...